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Abstract
Background: The spread of Neisseria gonorrhoeae strains with mosaic penA alleles and reduced susceptibility to
extended-spectrum cephalosporins is a major public health problem. While much work has been performed
internationally, little is known about the genetics or molecular epidemiology of N. gonorrhoeae isolates with
reduced susceptibility to extended-spectrum cephalosporins in the United States. The majority of N. gonorrhoeae
infections are diagnosed without a live culture. Molecular tools capable of detecting markers of extended-spectrum
cephalosporin resistance are needed.
Methods: Urethral N. gonorrhoeae isolates were collected from 684 men at public health clinics in California in
2011. Minimum inhibitory concentrations (MICs) to ceftriaxone, cefixime, cefpodoxime and azithromycin were
determined by Etest and categorized according to the U.S. Centers for Disease Control 2010 alert value breakpoints.
684 isolates were screened for mosaic penA alleles using real-time PCR (RTPCR) and 59 reactive isolates were subjected
to DNA sequencing of their penA alleles and Neisseria gonorrhoeae multi-antigen sequence typing (NG-MAST). To
increase the specificity of the screening RTPCR in detecting isolates with alert value extended-spectrum
cephalosporin MICs, the primers were modified to selectively amplify the mosaic XXXIV penA allele.
Results: Three mosaic penA alleles were detected including two previously described alleles (XXXIV, XXXVIII) and
one novel allele (LA-A). Of the 29 isolates with an alert value extended-spectrum cephalosporin MIC, all possessed
the mosaic XXXIV penA allele and 18 were sequence type 1407, an internationally successful strain associated with
multi-drug resistance. The modified RTPCR detected the mosaic XXXIV penA allele in urethral isolates and urine
specimens and displayed no amplification of the other penA alleles detected in this study.
Conclusion: N. gonorrhoeae isolates with mosaic penA alleles and reduced susceptibility to extended-spectrum
cephalosporins are currently circulating in California. Isolates with the same NG-MAST ST, penA allele and
extended-spectrum cephalosporin MICs have caused treatment failures elsewhere. The RTPCR assay presented here
may be useful for the detection of N. gonorrheoae isolates and clinical specimens with reduced extended-spectrum
cephalosporin MICs in settings where antimicrobial susceptibility testing is unavailable. In an era of increasing
antimicrobial resistance and decreasing culture capacity, molecular assays capable of detecting extended-spectrum
cephalosporin of resistance are essential to public health.
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Background
Neisseria gonorrhoeae is the second most commonly re-
ported sexually transmitted infection in the United States
[1]. N. gonorrhoeae has demonstrated a remarkable ability
to acquire resistance to all the first-line antimicrobials pre-
viously used including sulfanilamides, penicillins, tetracy-
clines, macrolides, and fluoroquinolones [2-7]. Currently,
extended-spectrum cephalosporins are the only first-line
antimicrobials recommended for the empirical treatment
of uncomplicated gonorrhea in many countries. In the
United States, the prevalence of isolates with reduced
susceptibility to cefixime (CFM) has resulted in dual
treatment with ceftriaxone (CRO) plus azithromycin
(AZM) or doxycycline being the only Centers for Disease
Control and Prevention (CDC) recommended treatment
regimen [8]. N. gonorrhoeae strains with reduced sus-
ceptibility to extended-spectrum cephalosporins have
been reported worldwide [9-19] and treatment failures
with oral and injectable extended-spectrum cephalospo-
rins have been reported in Europe, Africa, Asia, Australia
and North America [20-29]. Recently, extensively-drug
resistant N. gonorrhoeae strains have also been reported
in Japan [17], France [23] and Spain [30] that displayed
high-level resistance to CFM and CRO.
N. gonorrhoeae isolates with reduced susceptibility to
extended-spectrum cephalosporins have been linked to
altered penicillin-binding protein 2, encoded by the penA
gene. These penA alleles were termed “mosaic” because
their DNA sequence appears to have been formed through
homologous recombination events with other Neisseria
spp. that are naturally resistant to extended-spectrum
cephalosporins [10]. In 2009, isolates with mosaic penA al-
leles (XXXIV, XXXVIII) were first described in the United
States and were associated with reduced susceptibility to
CFM in San Francisco isolates [18]. Neisseria gonorrhoeae
multi-antigen sequence typing (NG-MAST) revealed that
these isolates were sequence type (ST) 1407, which has
since become a highly prevalent multi-drug resistant strain
in Europe [31] and Japan [32].
In the US, surveillance of N. gonorrhoeae antimicrobial
resistance is conducted by the CDC Gonococcal Isolate
Surveillance Program (GISP), which collects isolates
from men presenting at public health clinics in 28 coun-
ties including four in California. Although extensive anti-
microbial susceptibility testing data is collected about the
phenotypic characteristics of these isolates [33,34], little is
known about the genetics or molecular epidemiology of
isolates with reduced susceptibility to extended-spectrum
cephalosporins in the US. To investigate the association
between strains harboring mosaic penA alleles and re-
duced extended-spectrum cephalosporin susceptibilities
in California, N. gonorrhoeae isolates collected from
the four California GISP sites in 2011 were analyzed.
Minimum inhibitory concentrations (MICs) to CRO,
CFM, cefpodoxime (CPD) and AZM were determined
by Etest and categorized according to the 2010 CDC alert
value breakpoints [35]. Isolates were then screened for the
presence of a mosaic penA allele using real-time PCR
(RTPCR) [36] and reactive isolates were subjected to DNA
sequencing of their penA alleles and NG-MAST.
Detecting N. gonorrhoeae strains with reduced suscepti-
bility to cephalosporins is a challenge in the U.S. The vast
majority of N. gonorrhoeae infections are diagnosed using
nucleic acid amplification testing (NAAT) methods where
no live organism is available. In an era of increasing anti-
microbial resistance and decreasing laboratory culture
capacity, molecular assays capable of detecting markers of
resistance are essential tools for public health surveillance.
Therefore, we developed a novel RTPCR capable of specif-
ically detecting the mosaic XXXIV penA allele and other
closely related mosaic penA alleles that have been associ-
ated with extended-spectrum cephalosporin treatment
failures [23,24,37] and validated its use on urethral isolates
and clinical urine specimens.
Methods
Human subjects
Isolates and clinical specimens used in this study were
collected for public heath surveillance and de-identified
prior to antimicrobial susceptibility testing, thus this work
was considered public health practice and was exempt
from human subjects regulations [38]. This category of
research is not considered human subjects research and
is not subject to Institutional Review Board oversight.
Isolate and specimen collection
During 2011, urethral isolates (N = 684) were collected
from men visiting public health clinics participating in
GISP in Los Angeles, San Francisco, San Diego and
Orange counties in California as described previously
[39]. De-identified N. gonorrhoeae positive urine speci-
mens matched to urethral isolates with the mosaic
XXXIV penA allele (N = 3), N. gonorrhoeae negative
urine specimens (N = 24) and N. gonorrhoeae negative
pharyngeal swab specimens (N = 20) were obtained
from the San Francisco Department of Public Health
Laboratory in 2012. Urethral isolates and matched urine
specimens were collected during the same clinic visit.
Etest
Etest antimicrobial susceptibility testing was completed
on 678 isolates for CRO, 351 isolates for CPD, 332 iso-
lates for CFM and 682 isolates of AZM using chocolate
agar as described previously [39]. The lower numbers of
isolates tested by CFM and CPD resulted from a mid-year
change to the testing protocol where CPD was replaced by
CFM in the antimicrobial susceptibility testing panel.
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Sample preparation
Isolates were prepared for penA DNA sequencing, RTPCR
and NG-MAST by extracting DNA from 200 μL of liquid
culture using the QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany) on the automated QIAcube platform and were
stored at −40°C until used. Clinical specimens were pre-
pared for RTPCR by extracting DNA from 200 μL of the
APTIMA specimen buffer using the QIAamp DNA Mini
Kit on the automated Qiacube platform and were stored
at −40°C until used.
Quality control
For every Etest batch, two N. gonorrhoeae isolates with
predetermined MICs were included as quality control
strains. MICs for Etest control strains were determined
through repeat testing by the SFDPH laboratory. The
SF-2010-09-09 control strain was non-reactive by the
screening RTPCR and had non-alert value MICs to all four
antimicrobials (CRO= 0.016 μg/mL, CPD = 0.016 μg/mL,
CFM= 0.016 μg/mL, AZM= 0.032 μg/mL). The SF-2009-
11-07 control strain was reactive by the screening RTPCR,
had the mosaic XXXIV penA allele and had alert value
MICs to the three extended-spectrum cephalosporins,
but not AZM (CRO = 0.125 μg/mL, CPD = 1.5 μg/mL,
CFM = 0.19 μg/mL, AZM = 0.032 μg/mL). Etest batches
passed quality control if the MICs for both control
strains were within ± 1 log2 of the predetermined MIC.
For every RTPCR batch, extracted DNA from the SF-
2009-11-07 was used as a positive control and a negative
water control was included.
Detection of mosaic penA alleles
A TaqMan RTPCR was used to detect penA alleles with
the mosaic structure as described previously [36]. Briefly,
5 μL of extracted DNA from each isolate was used as the
template in a 20 uL reaction mix containing LightCycler
FastStart DNA Master HybProbe master mix (Roche
Diagnostics, Mannheim, Germany) and 1 uM, 250 nM
and 5 mM of primers, probe and MgCl2, respectively.
Primers and probe used are shown in Table 1. The follow-
ing amplification conditions were used: 2 min at 50°C,
10 min at 95°C, and 40 cycles of 15 s at 95°C and 60 s at
60°C. The samples were analyzed on a Roche LightCycler
2.0 and were declared positive if their curves rose above
2.0 fluorescence before cycle 35. RTPCR crossing points,
the cycle at which the sample’s fluorescence rises above
background, were automatically calculated using the
Roche LightCycler 2.0 software package and the absolute
quantitation setting.
PenA DNA sequencing
Isolates reactive by the screening RTPCR were subjected
to penA DNA sequencing as described previously [18].
Briefly, 5 μL of extracted DNA from each isolate was
used as the template in a 20 μL reaction mix using
LightCycler FastStart DNA Master HybProbe master
mix (Roche Diagnostics, Mannheim, Germany). The
penA gene was sequenced in two pieces with one amp-
lification reaction covering the first half of the gene and
another amplification reaction covering the second half.
The primers used are shown in Table 1. The samples
were analyzed on a Roche LightCycler 2.0 and the amp-
lification products were purified using the QiaQuick
PCR Purification Kit (Qiagen, Hilden, Germany) on the
automated Qiacube platform. Sequencing was com-
pleted by MCLAB Inc. (South San Francisco, CA) and
Elim Biopharmaceuticals (Hayward, CA) using the same
primers that were used for amplification.
NG-MAST
The por and tbpB genes from isolates with alert value
cephalosporin MICs were amplified and sequenced as
described previously [40]. Briefly, 5 μL of extracted DNA
from each isolate was used as the template in a 20 uL re-
action mix containing LightCycler FastStart DNA Master
HybProbe master mix (Roche Diagnostics, Mannheim,
Germany). The samples were analyzed on a Roche Light-
Cycler 2.0 and the amplification products were purified
using the QiaQuick PCR Purification Kit (Qiagen, Hilden,
Germany) on the automated Qiacube platform. Sequen-
cing was completed by MCLAB (South San Francisco,
CA) and Elim Biopharmaceuticals (Hayward, CA) using
the same primers that were used for amplification. NG-
MAST sequence types (STs) were obtained by uploading
trimmed sequences to the NG-MAST database at
http://www.ng-mast.net.
Table 1 Oligonucleotides used for RTPCR and
amplification and sequencing of penA, por and tbpB
Primer DNA sequence
Ochiai RTPCR forward 5′-GTTGGATGCCCGTACTGGG-3′
Ochiai RTPCR reverse 5′-ACCGATTTTGTAAGGCAGGG-3′
Ochiai RTPCR probea 5′-CGGCAAAGTGGATGCAACCGA-3′
Modified RTPCR forward 5′-TCAATACGCCTGCCTATGAG-3′





penA forward 1st half 5′-GCATCAGGATAATAATAACGAGAAG-3′
penA reverse 1st half 5′-TGTAAGGCAGGGTATTGAAT-3′
penA forward 2nd half 5′-GTTGGATGCCCGTACTGGG-3′
penA reverse 2nd half 5′-CAGCCAAAGGGGTTAACTTGCTGAAC-3′
aCovalently bonded to a 5-6-carboxyfluorescein-3-6-carboxytetramethylrhodamine
fluorophore.
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Detection of mosaic XXXIV penA alelle
A modified TaqMan RTPCR was developed to specific-
ally amplify the mosaic XXXIV penA allele. The mosaic
XXXIV, CI [23], XXXIV with T534A amino acid alteration
[24] and X [37] penA alleles share sequence identity in the
region detected by the modified RTPCR (bp 836 – bp
1066). Amplification specificity was accomplished by
designing the forward primer with internal mismatches
and a terminal 3′ mismatch to prevent the amplification
of mosaic penA alleles detected in this study that were
not associated with alert value extended-spectrum
cephalosporin MICs (XXXVIII, LA-A) [see multiple se-
quence alignment shown in Additional file 1]. The reac-
tion conditions used were identical to the screening
RTPCR. Primers and probe used are shown in Table 1.
Urine specimens (N = 27) and pharyngeal swab speci-
mens (N = 20) were tested using the APTIMA Combo
2 (Gen-Probe, San Diego, CA) to determine whether
N. gonorrhoeae was present prior to testing by the
modified RTPCR.
Data analysis
Isolates with alert value MICs were classified according
to the 2010 CDC GISP alert value breakpoints, which
were 0.125, 0.25, 0.25, and 2.0 μg/mL for CRO, CPD,
CFM and AZM respectively [35]. For this study, penA
genotypes were defined by 100% identity at the nucleo-
tide sequence level. DNA sequences were trimmed and
aligned using MEGA 5.05 and the TeXshade package in
LaTeX. All sequences presented in this study are publicly
available through Genbank at the National Center for
Biotechnology Information (http://www.ncbi.nlm.nih.gov/
genbank). Genbank accession numbers for mosaic penA
alleles XXXIV, XXXVIII, LA-A and wild-type (LM306) are
[Genbank:GU723422], [Genbank:HQ204565], [Genbank:
KC192769] and [Genbank:M32091], respectively.
Results
Phenotypic surveillance of 684 isolates collected in 2011
Overall, 15/678 isolates displayed alert value CRO MICs,
21/351 isolates displayed alert value CPD MICs and 2/682
isolates displayed alert value AZM MICs. No isolates with
an alert value CFM MIC were observed and both isolates
with alert value AZM MICs had extended-spectrum
cephalosporin MICs below the alert value breakpoints.
Genotypic surveillance of mosaic penA alleles in 684
isolates collected in 2011
Overall, 59/684 isolates were reactive by the screen-
ing RTPCR, indicating the presence of a mosaic
penA allele. DNA sequencing revealed that 39 iso-
lates possessed the mosaic XXXIV penA allele, four
isolates possessed the mosaic XXXVIII penA allele
and sixteen isolates possessed a novel mosaic penA
allele that will be referred to as LA-A. Of isolates
reactive by the screening RTPCR, 15/59 displayed an
alert value CRO MIC and 21/59 displayed an alert
value CPD MIC.
Figure 1 shows a full length multiple alignment of
the translated amino acid sequences of mosaic penA
alleles detected in this study. The mosaic XXXIV penA
allele has all three amino acid changes (I312M, V316T,
and G545S) that have previously been associated with
reduced susceptibility to oral extended-spectrum ceph-
alosporins [37,41]. The mosaic XXXVIII and LA-A
penA alleles both have two of these three amino acid
changes (I312M, V316T). None of the mosaic penA
alleles found in this study have the recently described
amino acid change (A501P) found in the mosaic CI
penA allele from an extensively-drug resistant gono-
coccal strain that displayed high level resistance to
both CFM and CRO [23,30].
Association of the mosaic XXXIV penA allele with alert
value extended-spectrum cephalosporin MICs
Figure 2 shows box plots of MIC distributions by penA
genotype. The mosaic XXXIV penA allele was associated
with elevated MICs for all three extended-spectrum
cephalosporins, although for CRO and CFM, the majority
of MICs remained below the alert value breakpoints. Of
isolates with the mosaic XXXIV penA allele, 15/39 dis-
played an alert value CRO MIC and 21/24 displayed an
alert value CPD MIC. All isolates with the mosaic
XXXVIII, mosaic LA-A and non-reactive penA alleles
had non-alert value extended-spectrum cephalosporin
MICs. Both isolates that displayed alert value AZM
MICs were non-reactive by the screening RTPCR and
had non-alert value extended-spectrum cephalosporin
MICs.
NG-MAST of 59 isolates with mosaic penA alleles
Table 2 shows the por alleles, tbpB alleles and NG-
MAST sequence types (STs) of isolates with a mosaic
penA allele. Of the 39 isolates with the mosaic XXXIV
penA allele, 24 were ST1407 (tbpB 110, por 908). In
isolates with the mosaic XXXIV penA allele and STs
other than ST1407, tbpB allele 110 was found in every
isolate except one, which had the closely related tbpB
allele 1431 (99.5% sequence identity with tbpB 110). Of
the four isolates with the mosaic XXXVIII penA allele,
all were ST1407. Of the 16 isolates with the mosaic
LA-A penA allele, 10 were ST7268 (tbpB 18, por 4340).
In isolates with the mosaic LA-A penA allele and STs
other then 7268, tbpB allele 18 was found in three iso-
lates, one isolate had tbpB allele 1429 (93.1% sequence
identity with tbpB 18) and one isolate had tbpB allele
1430 (94.6% sequence identity with tbpB 18).
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Figure 2 Box plots of MIC distributions by penA genotype. N= 678, 351, 332 and 682 for CRO, CPD, CFM and AZM respectively. Boxes indicate the
25th, 50th, and 75th percentiles. Whiskers indicate the lowest datum within 1.5 IQR of the lower quartile, and the highest datum within 1.5 IQR of the
upper quartile. Outliers are shown as gray circles. Gray horizontal bars indicate the alert value breakpoint for each antimicrobial.
Figure 1 Multiple alignment of translated amino acid sequences of mosaic penA alleles. Comparison of the translated amino acid
sequences for isolates with mosaic penA alleles detected in this study (XXXIV, XXXVIII and LA-A) to the wild-type sequence (LM306). Boxed residues
represent amino acid changes associated with reduced susceptibility to oral extended-spectrum cephalosporins.
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Modified RTPCR for the detection of the mosaic XXXIV
penA allele
Table 3 shows results of the modified RTPCR performance
in detecting the mosaic penA XXXIV allele in a validation
panel of 71N. gonorrhoeae isolates, 27 urine specimens
and 20 pharyngeal swab specimens. The modified RTPCR
was reactive in 39/39 urethral isolates containing the mo-
saic XXXIV penA allele and 3/3 urine specimens that were
matched to urethral isolates possessing the mosaic XXXIV
penA allele. No reactivity was seen in isolates with the
mosaic XXXVIII, LA-A or penA alleles non-reactive by
the screening RTPCR. All N. gonorrhoeae negative urine
specimens and pharyngeal swab clinical specimens were
also non-reactive. Based upon testing of the validation
panel of 71 isolates, the sensitivity and specificity of the
modified RTPCR in detecting alert value CRO MICs were
100% and 57% respectively.
Discussion
N. gonorrhoeae has an extensive history of antimicrobial
resistance and has demonstrated that it is capable of
utilizing a variety of mechanisms to escape antimicrobial
pressure. Extended-spectrum cephalosporins have been
the CDC recommended treatment only since 2007, but
it appears that their usefulness is already on the decline. In
2010, the CDC issued treatment guidelines recommending
dual therapy with CFM plus AZM or doxycyline due to
concerns about increasing antimicrobial resistance. In
2012, the CDC again updated its recommendations and
abandoned oral extended-spectrum cephalosporins in
favor of dual therapy with CRO plus AZM or doxycycline.
The data here support this recommendation since no iso-
lates were found with alert value MICs to both AZM and
an extended-spectrum cephalosporin. Two isolates with
alert value MICs to AZM were detected in San Francisco
and San Diego, however, so the emergence of dual-
resistant strains in California remains a possibility.
Three mosaic penA alleles were detected in this study
and a novel one was identified. The mosaic XXXIV and
XXXVIII penA alleles were both previously detected in
San Francisco in 2009 [18], while the LA-A penA allele
is novel. The mosaic XXXIV penA allele has all three
amino acid changes previously associated with reduced
susceptibility to oral extended-spectrum cephalosporins
[37]. Homology modeling studies have shown that these
amino acid changes result in conformational alterations
of the β-lactam-binding pocket and affect the ability of
extended-spectrum cephalosporins to bind, particularly
those with large R groups [42]. More recently, it has
been shown that these amino acid changes are epistatic
Table 2 NG-MAST sequence types of isolates with a
mosaic penA allele in California









24 10 XXXIV 110 908 1407
1 0 XXXIV 110 1388 2212
2 0 XXXIV 110 1903 3149
1 1 XXXIV 110 2622 4275
1 0 XXXIV 110 2684 4378
1 0 XXXIV 110 3424 5643
4 0 XXXIV 110 2700 5895
1 1 XXXIV 110 3669 6200
2 2 XXXIV 110 4544 7560
1 0 XXXIV 110 4599 7647
1 1 XXXIV 1431b 1900 7566
4 0 XXXVIII 110 908 1407
10 0 LA-A 18 4340 7268
2 0 LA-A 18 4546 7564
1 0 LA-A 18 4545 7646
1 0 LA-A 81c 4340 7561
1 0 LA-A 1429d 4340 7562
1 0 LA-A 1430e 4547 7565
aCRO alert value MIC ≥ 0.125 μg/mL.
btbpB allele 1431 is 2 bp different from tbpB allele 110.
ctbpB allele 81 is 27 bp different from tbpB allele 18.
dtbpB allele 1429 is 1 bp different from tbpB allele 18.
etbpB allele 1430 is 21 bp different from tbpB allele 18.
Table 3 Isolates and clinical specimens tested with the modified RTPCR
Specimen type Total no. No. CRO alerta Source penA genotypeb NAAT resultc RTPCR resultd
Isolate 39 15 Urethral XXXIV + +
6 0 Urethral XXXVIII + -
6 0 Urethral LA-A + -
20 0 Urethral Non-reactive + -
Clinical Specimen 3 ND Urine XXXIV + +
24 ND Urine ND - -
20 ND Pharynx ND - -
aCRO alert value MIC ≥ 0.125 μg/mL.
bND = Not determined.
cTested by APTIMA Combo 2.
dTested by the modified RTPCR presented in this study.
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and only result in higher MICs in the context of other
mutational changes in penA [41]. Although the mosaic
XXXVIII and LA-A penA alleles both have two of these
amino acid changes, the distributions of extended-
spectrum cephalosporin MICs for isolates with these
penA alleles were similar to those with non-reactive
penA alleles. These data support the hypothesis that
the I312M and V316T amino acid changes act syner-
gistically with the G545S amino acid change and that
they are necessary, but not sufficient, to produce elevated
oral extended-spectrum cephalosporin MICs.
The mosaic XXXIV penA allele detected in this study
is concerning because it was found in isolates with
extended-spectrum cephalosporin MICs that have been
reported in isolates associated with treatment failures.
Since first being published in 2009, the mosaic XXXIV
penA allele has been found worldwide and is now associ-
ated with ST1407 strains and reduced susceptibility to
extended-spectrum cephalosporins. A pharyngeal ST1407
isolate with the mosaic XXXIV penA allele recently caused
a CRO treatment failure in Slovenia [29] and strains with
closely related mosaic penA alleles have caused treatment
failures in France (mosaic CI) [23], Austria (mosaic
XXXIV with T534A amino acid alteration) [24] and Hong
Kong (mosaic X) [37]. The mosaic XXXIV penA allele is
only a single amino acid change (A501P) different from
the mosaic CI penA allele described in extensively-drug
resistant isolates from France and Spain that exhibited
high-level resistance to both oral and injectable extended-
spectrum cephalosporins [23,30]. This additional mutation
might be capable of increasing CRO MICs from the
elevated levels seen in this study (CRO MIC = 0.094-
0.25 μg/mL) to levels at which CRO treatment failures
have occurred even with much higher 1 g doses (CRO
MIC = 1.0-2.0 μg/mL) [38]. The extensively-drug resistant
isolates described in France and Spain were also ST1407,
indicating a genetically similar background. It is possible,
however, that determinants of resistance other than penA
also affect the extended-spectrum cephalosporin MICs
observed.
In 2009, the mosaic XXXIV and XXXVIII penA alleles
were described only in ST1407 isolates and a very closely
related isolate (ST1513, tbpB 110, por 971, 99.8% similar
to por 908) in San Francisco and appeared to be spread-
ing in a clonal fashion. The mosaic XXXVIII penA allele
has remained clonal within ST1407 in California, while
the mosaic XXXIV penA allele was found in 10 STs
other than ST1407 in 2011. In isolates with the mosaic
XXXIV penA allele and STs other than ST1407, the
tbpB allele was the same as ST1407 (tbpB allele 110) or
was a closely related tbpB allele (tbpB allele 1431,
99.5% similar to tbpB 110). ST1407 remains the domin-
ant ST associated with reduced extended-spectrum ceph-
alosporin susceptibilities in California, but strains with
unrelated STs now carry the mosaic XXXIV penA allele.
Genomic mapping of ST1407 and ST5895 isolates from
San Francisco recently detailed the transfer of the mo-
saic XXXIV penA allele into a completely different gen-
etic background [43]. In this study, four ST5895
isolates with the mosaic XXXIV penA allele were found
in Los Angeles, Orange County and San Diego, indicat-
ing that this strain is likely circulating throughout Cali-
fornia. Unfortunately, the horizontal spread of the
mosaic XXXIV penA allele into new STs makes track-
ing the spread of extended-spectrum cephalosporin re-
sistance with NG-MAST problematic.
Of note is the fact that the mosaic XXXIV penA allele
was only found in isolates with tbpB allele 110 or a very
closely related allele (tbpB 1431, 99.6% similar to tbpB
allele 110). In the N. gonorrhoeae genome, penA is located
~50 kb downstream of tbpB. The linkage between these
two loci likely explains the high level of clonality of tbpB
alleles in isolates with the mosaic XXXIV penA allele.
The linkage between penA and tbpB was also evident in
isolates with the mosaic LA-A penA allele where 13/16
isolates had tbpB 18.
Detecting strains with reduced susceptibility to extended-
spectrum cephalosporins is a challenge in the U.S. The vast
majority of N. gonorrhoeae infections are diagnosed using
nucleic acid-based methods where no live organism is
present. Without a culture and antimicrobial susceptibility
testing, molecular assays are currently the only option
available for detecting isolates with reduced susceptibility
to extended-spectrum cephalosporins. The modified
RTPCR presented here is a simple and rapid tool capable
of specifically detecting isolates or urine specimens that
may have alert value extended-spectrum cephalosporin
MICs. The assay may find utility in the surveillance and
epidemiological investigation of strains with reduced
susceptibility to extended-spectrum cephalosporins.
This assay, however, has several limitations. The mosaic
penA alleles which the assay was designed to discriminate
between were detected in California in 2011. It is possible
that other mosaic penA alleles are circulating elsewhere
that produce elevated extended-spectrum cephalosporin
MICs, but do not share the region of sequence identity
that the modified RTPCR detects. Also, the modified
RTPCR should be used with caution on pharyngeal speci-
mens because of the potential for cross-reactivity with
penA alleles from other Neisseria spp. The assay per-
formed well on N. gonorrhoeae positive urine specimens
matched to isolates with the mosaic XXXIV penA allele,
but only a small number of specimens were available for
testing.
The main limitation of this study is the sampling
strategy used to collect N. gonorrhoeae isolates. The
samples were collected in parallel with the CDC GISP
which collects isolates only from men. Additionally, the
Gose et al. BMC Infectious Diseases 2013, 13:570 Page 7 of 9
http://www.biomedcentral.com/1471-2334/13/570
samples were collected from public health clinics whose
populations may not be representative of the general
population and are known to oversample MSM [44].
Since MSM populations have historically been associated
with higher rates of antimicrobial resistance, it is possible
that these data overestimate the prevalence of alert value
isolates in the general population [34]. Another limitation
was the use of RTPCR to screen isolates for the presence
of a mosaic penA allele. The screening RTPCR detected a
region of shared sequence identity found in many mosaic
penA alleles, but it is possible that other mosaic alleles
were present that are non-reactive with this assay.
Conclusion
In conclusion, N. gonorrhoeae isolates with mosaic penA
alleles and reduced susceptibility to extended-spectrum
cephalosporins are currently circulating in California.
Isolates with the same NG-MAST ST, penA allele and
extended-spectrum cephalosporin MICs have caused veri-
fied treatment failures elsewhere. Enhanced surveillance
efforts such as the use of the molecular assays to detect re-
sistance determinants and the implementation of test of
cure protocols will be necessary to ensure that empirical
treatment remains effective.
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